FAPI-74 PET/CT in Adults With Fibrosis

Conditions

• Fibrosis (Morphologic Abnormality)

Eligibility Criteria

Sex

ALL

Age

21 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• [F-18]-FAPI-74 — DRUG
  A positron-emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo expression of FAP with positron emission tomography (PET/CT).

Study Details

This protocol is intended as a basket protocol designed to evaluate the use of Fibroblast Activating Protein (FAP) PET/CT in imaging the presence of fibrosis caused by a variety of medical conditions where fibrosis is believed to lead to pathological effects and poor prognosis.

Key Dates

Start date

Jul 16, 2024

Status verified

Feb 2026

Primary completion

Jul 30, 2027

Completion

Jul 30, 2027

Study Design

Enrollment

45 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Arms

• Experimental: FAPI-74 PET/CT Scan
  Head and neck cancer (up to 15 subjects), post tubercular lung disease (PTLD, up to 10 subjects), Cardiac Sarcoidosis and Exploratory (up to 10 subjects each) with fibrosis-inducing medical conditions that are known or suspected to cause tissue fibrosis (e.g. cancer-associated, postinfection, post-radiation, pre/post-transplant, cardiac, liver, kidney or pulmonary fibrosis).

Primary Outcome Measure

Overall FAPI-74 PET/CT Image Analysis [ Time Frame: 3 years ]

Central Contacts

• Erin Schubert
  215-573-6569
  [email protected]
• Mary Hansbury
  215-746-8192
  [email protected]

Locations (1)

Find similar trials in Philadelphia, PA